Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.32 USD | +0.68% | -19.03% | +41.55% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.55% | 282M | |
-1.42% | 41.52B | |
+42.15% | 39.9B | |
+1.97% | 38.83B | |
-14.19% | 26.05B | |
+1.82% | 23.78B | |
-24.55% | 18.26B | |
-4.07% | 11.65B | |
+21.36% | 11.53B | |
+8.20% | 11.2B |
- Stock Market
- Equities
- ENTA Stock
- News Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals : RBC Capital Adjusts Enanta Pharmaceuticals PT to $45 From $52 Following Q4 Results, Maintains Sector Perform Rating